急性髓系白血病中eIF4E高表达与疾病进展相关

摘要

本研究检测未治疗、未缓解/复发及缓解期间急性髓系白血病(AML)和其他良性血液病患者骨髓细胞中eIF4E基因表达水平并分析其与疾病进展的关系.采用SYBR Green Ⅰ荧光定量PCR和相对定量分析法检测30例AML患者(M2型6例,M3型5例,M4型8例,M5型10例,M6型1例),11例AML化疗后完全缓解患者和20例非肿瘤性血液病患者骨髓单个核细胞的eIF4E表达情况,以β2微球蛋白基因(β2M)作为内参,采用公式2-ΔCt×100％计算eIF4E基因表达水平.结果表明:AML未治疗及未缓解/复发组患者骨髓细胞eIF4E表达水平(7.098±5.544)％明显高于非肿瘤患者(0.248±0.163)％ (P ＜0.01)和化疗后完全缓解患者(0.964±0.312)％(P＜0.01),各AML亚型之间不存在统计学差异,尽管M4、M5亚型的表达水平相对较高.非白血病患者与缓解患者比较,eIF4E表达水平不存在显著性差异.结论:eIF4E基因在急性髓系白血病细胞中出现高表达,并随着疾病的缓解而明显降低,因此eIF4E有可能作为监测白血病进展的一项参数.%The aim of this study was to detect the expression level of eIF4E gene in patients with non-treated, remission and non-remission/relapse acute myeloid leukemia( AML) , and other non-malignant haematologic diseases so as to analyze and reveal the relationship of eIF4E gene expression with AML progression. SYBR Green I RT-PCR was used to assay the expression level of eIF4E mRNA extracted from bone marrow mononuclear cells in 30 patients with AML (6 in M2, 5 in M3,8 in M4,10 in M5,l in M6) and 20 patients with non-malignant hematologic diseases. The p2-microglu-bin( β2M) was used as internal reference and the formula 2 -△Ct x 100% was applied to calculate the expression level of eIF4E gene. The results showed that the eIF4E expression level (7. 098 ±5. 544)% in patients with non-treated and non-remitted/relapsed AML was significantly higher than that in patients with remission (0.964 ±0.312)% (P<0.01) and non-malignant hematologic diseases (0. 248 ±0. 163)% (P <0. 01). There was no difference between latter two group patients, even though the expression level of eIF4E gene in patients with M4 and M5 was higher. As compared with non-malignant hematologic diseases, the expression level of eIF4E gene of patients with remission patients showed no significant difference. It is concluded that the over-expression of eIF4E gene has been found in patients with AML, and its level obviously decreases along with remission of disease, thus the eIF4E gene may be a surveillance parameter for disease progression.